Skip to main content
. Author manuscript; available in PMC: 2023 Aug 15.
Published in final edited form as: Cancer Res. 2023 Feb 15;83(4):626–640. doi: 10.1158/0008-5472.CAN-22-0232

Figure 3. Combined Anti- PDL1 and Anti-CTLA4 delays tumor progression in MYC-HCC.

Figure 3.

A. Experimental scheme of MYC-HCC treatment with IgG control (n=5), PDL1 antibody (n=5), CTLA4 antibody (n=5), or their combination (n=5) (created using Biorender.com).

B. Weekly MRI showing tumor progression in representative MYC-HCC mice in the 4 treatment groups (n=5 each group).

C. Quantification of volumetric tumor measurement using MRI of MYC-HCC mice in the 4 treatment groups (n=5 each group).

D. End-of-treatment gross appearance, histology of representative MYC-HCC mice in the 4 treatment groups (n=5 each group).

E. Quantification of liver tumor burden at end-of-treatment of MYC-HCC mice in the 4 treatment groups (n=5 each group).

**p<0.01, ***p<0.0001